Danielle Antalffy
Stock Analyst at UBS
(3.57)
# 2,235
Out of 4,609 analysts
608
Total ratings
51.2%
Success rate
2.8%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintained: Buy | $95 → $96 | $82.93 | +15.76% | 41 | Jul 28, 2026 | |
| TNDM Tandem Diabetes Care | Initiated Coverage: Hold | $22 → $18 | $18.86 | -4.56% | 28 | Jul 28, 2026 | |
| SGHT Sight Sciences | Initiated Coverage: Buy | $11 → $7 | $6.85 | +2.19% | 7 | Jul 28, 2026 | |
| RXST RxSight | Initiated Coverage: Hold | $9 → $5.5 | $5.58 | -1.43% | 12 | Jul 28, 2026 | |
| BBNX Beta Bionics | Initiated Coverage: Buy | $24 → $22 | $13.89 | +58.39% | 3 | Jul 28, 2026 | |
| ABT Abbott Laboratories | Reiterated: Buy | $158 → $135 | $106.16 | +27.17% | 38 | Apr 20, 2026 | |
| BSX Boston Scientific | Rated: Buy | $120 → $105 | $49.37 | +112.68% | 42 | Mar 17, 2026 | |
| ISRG Intuitive Surgical | Rated: Hold | $570 → $550 | $373.58 | +47.23% | 10 | Mar 17, 2026 | |
| JNJ Johnson & Johnson | Rated: Buy | $214 → $280 | $255.66 | +9.52% | 34 | Mar 17, 2026 | |
| SYK Stryker | Rated: Hold | $400 → $380 | $336.13 | +13.05% | 20 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $2.25 | $4.56 | -50.66% | 15 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $62 → $30 | $18.59 | +61.38% | 9 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $400 | $131.60 | +203.95% | 43 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $55 | $39.61 | +38.85% | 26 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $104 | $86.00 | +20.93% | 40 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 → $19 | $27.53 | -30.98% | 26 | Feb 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $89 → $67 | $60.03 | +11.61% | 21 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $94 → $90 | $88.47 | +1.73% | 42 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $86 → $89 | $97.03 | -8.27% | 18 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $22.72 | +5.66% | 1 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $145 → $150 | $169.45 | -11.48% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $50 | $27.51 | +81.75% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 → $16 | $15.17 | +5.47% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $2.25 | $8.41 | n/a | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $101.89 | n/a | 10 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $13.76 | n/a | 11 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $2.34 | n/a | 6 | May 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $5.52 | n/a | 5 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $275 | $177.18 | n/a | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $55 | $5.10 | n/a | 10 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $45.02 | n/a | 14 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $45.22 | n/a | 6 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $0.3901 | n/a | 14 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $6.60 | n/a | 20 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $3 | $5.18 | n/a | 14 | Aug 9, 2021 |
DexCom
Jul 28, 2026
Maintained: Buy
Price Target: $95 → $96
Current: $82.93
Upside: +15.76%
Tandem Diabetes Care
Jul 28, 2026
Initiated Coverage: Hold
Price Target: $22 → $18
Current: $18.86
Upside: -4.56%
Sight Sciences
Jul 28, 2026
Initiated Coverage: Buy
Price Target: $11 → $7
Current: $6.85
Upside: +2.19%
RxSight
Jul 28, 2026
Initiated Coverage: Hold
Price Target: $9 → $5.5
Current: $5.58
Upside: -1.43%
Beta Bionics
Jul 28, 2026
Initiated Coverage: Buy
Price Target: $24 → $22
Current: $13.89
Upside: +58.39%
Abbott Laboratories
Apr 20, 2026
Reiterated: Buy
Price Target: $158 → $135
Current: $106.16
Upside: +27.17%
Boston Scientific
Mar 17, 2026
Rated: Buy
Price Target: $120 → $105
Current: $49.37
Upside: +112.68%
Intuitive Surgical
Mar 17, 2026
Rated: Hold
Price Target: $570 → $550
Current: $373.58
Upside: +47.23%
Johnson & Johnson
Mar 17, 2026
Rated: Buy
Price Target: $214 → $280
Current: $255.66
Upside: +9.52%
Stryker
Mar 17, 2026
Rated: Hold
Price Target: $400 → $380
Current: $336.13
Upside: +13.05%
Mar 2, 2026
Maintained: Hold
Price Target: $2.5 → $2.25
Current: $4.56
Upside: -50.66%
Mar 2, 2026
Maintained: Buy
Price Target: $62 → $30
Current: $18.59
Upside: +61.38%
Feb 19, 2026
Reiterated: Buy
Price Target: $400
Current: $131.60
Upside: +203.95%
Feb 18, 2026
Maintained: Buy
Price Target: $58 → $55
Current: $39.61
Upside: +38.85%
Feb 17, 2026
Maintained: Hold
Price Target: $104
Current: $86.00
Upside: +20.93%
Feb 16, 2026
Maintained: Hold
Price Target: $21 → $19
Current: $27.53
Upside: -30.98%
Feb 13, 2026
Maintained: Hold
Price Target: $89 → $67
Current: $60.03
Upside: +11.61%
Feb 12, 2026
Maintained: Hold
Price Target: $94 → $90
Current: $88.47
Upside: +1.73%
Feb 11, 2026
Maintained: Sell
Price Target: $86 → $89
Current: $97.03
Upside: -8.27%
Feb 9, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $22.72
Upside: +5.66%
Jan 28, 2026
Maintained: Buy
Price Target: $145 → $150
Current: $169.45
Upside: -11.48%
Jan 5, 2026
Maintained: Buy
Price Target: $57 → $50
Current: $27.51
Upside: +81.75%
Nov 6, 2025
Maintained: Hold
Price Target: $16 → $16
Current: $15.17
Upside: +5.47%
Mar 28, 2023
Initiated Coverage: Hold
Price Target: $2.25
Current: $8.41
Upside: n/a
May 17, 2022
Reiterated: Buy
Price Target: $100
Current: $101.89
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $12
Current: $13.76
Upside: n/a
May 10, 2022
Maintained: Buy
Price Target: $13
Current: $2.34
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $12
Current: $5.52
Upside: n/a
May 5, 2022
Rated: Hold
Price Target: $275
Current: $177.18
Upside: n/a
May 5, 2022
Rated: Buy
Price Target: $65 → $55
Current: $5.10
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $45
Current: $45.02
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $12 → $14
Current: $45.22
Upside: n/a
May 3, 2022
Rated: Buy
Price Target: $5
Current: $0.3901
Upside: n/a
Jan 10, 2022
Maintained: Hold
Price Target: n/a
Current: $6.60
Upside: n/a
Aug 9, 2021
Reiterated: Hold
Price Target: $2 → $3
Current: $5.18
Upside: n/a